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Introduction {#sec005}
============

It has long been known that vitamin D plays an important role in skeletal health. \[[@pone.0124168.ref001]\] Serum levels of vitamin D change with the seasons, exposure to sunlight and dietary intake and are inversely related to skin pigmentation and body mass index (BMI). \[[@pone.0124168.ref001]--[@pone.0124168.ref003]\] Vitamin D associations to extraskeletal outcomes such as cancer, cardiovascular disease, diabetes, autoimmune diseases and infections have also been reported. \[[@pone.0124168.ref004],[@pone.0124168.ref005]\] The evidence to support the latter associations does not come from randomized controlled trials so that the Institute of Medicine considers levels lower than 20 ng/ml as deficient based entirely on skeletal outcomes. \[[@pone.0124168.ref001]\] In contrast, considering evidence on skeletal as well as extraskeletal disease, the US Endocrine Society recommended that vitamin D deficiency be defined as a 25(OH)D level of 20 ng/mL or less and vitamin D insufficiency as 21 to 29 ng/mL for children and adults. \[[@pone.0124168.ref006]\]

Vitamin D is a key player in the innate immune system and in immune modulation; thus, it has been evaluated for prevention and treatment of different infections. \[[@pone.0124168.ref007]\] Its role in HIV disease is unclear, but deficiency of this vitamin has been reported with increasing frequency in HIV-infected patients. \[[@pone.0124168.ref008]--[@pone.0124168.ref011]\] Despite the high prevalence of vitamin D deficiency in this group of patients, it has been reported to be lower than that of the general population. \[[@pone.0124168.ref012],[@pone.0124168.ref013]\] In HIV-infected patients vitamin D levels may also depend on HIV treatment; efavirenz use is associated with lower levels \[[@pone.0124168.ref008],[@pone.0124168.ref012]\] while tenofovir use has been associated with higher levels of this vitamin. \[[@pone.0124168.ref012]\]

Our aims were to describe and compare the prevalence of vitamin D deficiency between HIV-negative and HIV-infected patients in a single healthcare system, and to determine risk factors for vitamin D deficiency in this population.

Methods {#sec006}
=======

This cross-sectional, retrospective study included all patients followed at the Atlanta VA Medical Center (VAMC) with the first 25-hydroxyvitamin D \[25(OH)D\] level determined between January 2007 and August 2010. 25(OH)D determinations were obtained as part of routine clinical care during this time period. This study had Institutional Review Board (IRB) approval from Emory University and the AtlantaVeteran´s Affairs Medical Center. All patients followed at the HIV AtlantaVeteran´s Affairs Medical Center Cohort Study (HAVACS) with a vitamin D level during this same time frame were also included. HAVACS database has had an IRB waiver from Emory University and the Atlanta VAMC since 1982. Patient records and information were anonymized and de-identified prior to analysis.

Specific demographic, clinical and laboratory data were obtained from electronic medical records. The liquid chromatography/tandem mass spectrometry method was used for measuring 25(OH)D (Quest Laboratories). 25(OH)D deficiency and insufficiency was defined as a level of \<20 and ≥20--\<30 ng/ml, respectively, based on previous assessments and published optimal Vitamin D levels for preventing adverse outcomes. \[[@pone.0124168.ref001],[@pone.0124168.ref002],[@pone.0124168.ref014]--[@pone.0124168.ref016]\] Standard, routine laboratory assays were used to measure serum chemistry tests. The glomerular filtration rate (GFR) was estimated by the Cockroft-Gault equation.

For the statistical analysis, Pearson's exact chi square and Wilcoxon two-sided tests were used for categorical and continuous variables, respectively. Variables examined included: age, gender, race, body mass index (BMI), month of the year the 25(OH)D levels were obtained (season) and HIV status. For the HIV-infected cohort, additional variables included specific risk factor for HIV, years since HIV diagnosis, nadir CD4 count, history of opportunistic infections, comorbidities, lab values (creatinine, parathyroid hormone (PTH), calcium, phosphorus levels, current CD4 T cell count, current HIV viral load), and antiretroviral (ARV) regimen. Variables that were significant on univariate analysis were included in a multivariate logistic regression model to determine independent risk factors associated with vitamin D deficiency. A p-value of \<0.05 was used to determine variables that remained significantly associated with Vitamin D deficiency. SAS (version 9.2; SAS Institute, Cary, NC) software was used to perform the analyses.

Results {#sec007}
=======

Total VA Population {#sec008}
-------------------

A total of 6288 veterans were included in the study. The overall prevalence of 25(OH)D deficiency was 40.7% (2558/6288). Median age was 61 years (range 22--97), 50.1% were black, and 88.5% male. The median BMI was 26. Close to 15% of the patients were HIV-infected and 55.7% of the 25(OH)D levels were drawn during the winter months. Significant associations with 25(OH)D deficiency in univariate analysis included: younger median age (59 vs. 63, p\<0.0001), black race (68.5 vs. 37.3%, p\<0.0001), male gender (86.9 vs. 89.6%, p 0.0011), higher median BMI (27 vs. 26, p = 0.0005), HIV-positive status (19.4 vs. 11.7%, p\<0.001), and levels drawn during the winter season (61.7 vs. 51.5%, p\<.0001) ([Table 1](#pone.0124168.t001){ref-type="table"}). There was higher prevalence of 25(OH)D deficiency among HIV-positive compared to HIV-negative patients (53.2% (95% CI: 51.6, 54.8) vs. 38.5% (95% CI: 37.2, 39.8), p \<0.001); this was true for all age groups ([Fig 1](#pone.0124168.g001){ref-type="fig"}). Median 25(OH)D levels were 24 ng/ml for HIV-negative patients and 19 ng/ml for HIV positive patients (p\<0.001). HIV positive patients were also more likely African American, younger, male and less obese ([Table 2](#pone.0124168.t002){ref-type="table"}). In multivariate analysis, independent risk factors for 25(OH)D deficiency included black race (odds ratio (OR) 3.34, 95% confidence interval (CI) 2.98--3.74), higher BMI (OR 1.02, 95% CI 1.01--1.03), and winter season (OR 1.70, 95% CI 1.52--1.90). There was a significant interaction between age and HIV status so that for each additional decade of life, people who were HIV-negative had an 8% reduction in the odds of 25(OH) D deficiency (OR 0.92, 95% CI 0.88--0.96 for every decade of life) compared to a 29% reduction for HIV-positive patients (OR 0.71, 95% CI 0.62--0.82 for every decade of life) ([Table 3](#pone.0124168.t003){ref-type="table"}).

![Mean Vitamin D Level by Age Group for HIV positive and HIV negative Patients.](pone.0124168.g001){#pone.0124168.g001}

10.1371/journal.pone.0124168.t001

###### Risk factors associated with Vitamin D deficiency, all patients; univariate analysis.

![](pone.0124168.t001){#pone.0124168.t001g}

  **Risk Factor**              **Vit D \< 20 (n = 2558)**   **Vit≥20D (n = 3730)**   **P value**
  ---------------------------- ---------------------------- ------------------------ -------------
  Median age (range)           59 (22--95)                  63 (22--97)              \<.0001
  Black race n (%)             1752 (68.5)                  1394 (37.3)              \<.0001
  Male gender n (%)            2224 (86.9)                  3343 (89.6)              0.0011
  Median BMI\* (range)         27 (12--62)                  26 (14--54)              0.0005
  HIV infection n (%)          496 (19.4)                   437 (11.7)               \<.0001
  Winter/spring season n (%)   1579 (61.7)                  1921 (51.5)              \<.0001

10.1371/journal.pone.0124168.t002

###### Characteristics of HIV-negative versus HIV positive patients.

![](pone.0124168.t002){#pone.0124168.t002g}

  **Characteristic**           **HIV negative (n = 5355)**   **HIV positive (n = 933)**   **P value**
  ---------------------------- ----------------------------- ---------------------------- -------------
  Age median (range)           63 (22--97)                   50 (24--86)                  \<.0001
  BMI median (range)           26 (12--62)                   26 (15--53)                  0.0002
  Black race n (%)             2425 (45.3)                   721 (77.4)                   \<.0001
  Vitamin D \<20 ng/ml n (%)   2062 (38.5)                   495 (53.2)                   \<.0001
  Male gender n (%)            4655 (86.9)                   910 (97.5)                   \<.0001
  Winter season n (%)          3112 (58.1)                   388 (41.6)                   \<.0001

10.1371/journal.pone.0124168.t003

###### Risk factors associated with Vitamin D deficiency, all patients; multivariate analysis.

![](pone.0124168.t003){#pone.0124168.t003g}

  **Risk factor**           **OR (95% CI)**
  ------------------------- ---------------------
  Black race                3.34 (2.98--3.74)
  Winter/spring season      1.70 (1.52--1.90)
  BMI                       1.02 (1.01--1.03)
  10-year increase in age   
  among HIV negative          0.92 (0.88--0.96)
  among HIV positive          0.71 (0.62--0.82)

HIV-positive population only {#sec009}
----------------------------

A total of 933 HIV infected patients were studied. The overall prevalence of 25(OH)D deficiency was 53.2% (496/933). Median age was 50 years (24--86), 77.3% were black, and 53.5% men who have sex with men (MSM). The median CD4 count and viral load at the time of the 25(OH)D level were 466 (2--2103) and \<48 copies, respectively. 56.7% of patients had an undetectable viral load; only 12.9% of patients had CD4 counts \<200 and 82% patients were on ARVs. The most frequent comorbid conditions included: obesity (BMI ≥ 25) (56.2%), hypertension (50.4%), smoking (44.1%), hepatitis C (17.9%), diabetes (14.4%), chronic kidney disease stage III or worse (GFR ≤ 60) (10.5%), cardiovascular disease (9.4%) and hepatitis B (8.4%). Significant associations with 25(OH)D deficiency in univariate analysis included: younger median age (48 vs. 52, p\<0.0001), black race (87.7 vs. 66.2%, p\<0.0001), higher median GFR (93 vs. 86, p\<0.0001), hepatitis B (10.1 vs. 6.4%, p = 0.04), median number of years since HIV diagnosis (10.9 vs. 12.5, p = 0.02), winter season (45.4 vs. 37.3%, p = 0.01), undetectable viral load (53.1 vs. 60.6%, p = 0.02), tenofovir use (57.7 vs. 65.9%, p = 0.01), protease inhibitor use (32.9 vs. 43.0%, p = 0.002) and no ARV use (21.2 vs. 13.0%, p = 0.001) ([Table 4](#pone.0124168.t004){ref-type="table"}). In multivariate analysis, independent risk factors for 25(OH)D deficiency included black race (OR 3.30, 95% CI 2.30--4.74), higher GFR (OR 1.01, 95% CI 1.00--1.01) and winter season (OR 1.37, 95% CI 1.03--1.83). Older age (OR 0.97, 95% CI 0.95--0.99) and tenofovir use (OR 0.58, 95% CI 0.37--0.89) were associated with less 25(OH)D deficiency ([Table 5](#pone.0124168.t005){ref-type="table"}).

10.1371/journal.pone.0124168.t004

###### Risk factors associated with Vitamin D deficiency, HIV-positive patients; univariate analysis.

![](pone.0124168.t004){#pone.0124168.t004g}

  **Risk Factor**                    **Vitamin D \<20 (n = 496) n/N (%)**   **Vitamin≥20 D (n = 437) n/N (%)**   **P value**
  ---------------------------------- -------------------------------------- ------------------------------------ -------------
  Age (median, range)                48 (25--77)                            52 (24--86)                          \<0.0001
  Race                                                                                                            
  Black                              434/723 (60.0)                         289/723 (40.0)                       \<0.0001
  Other                              61/208 (29.3)                          147/208 (70.7)                        
  Risk factor                                                                                                     
  MSM                                265/499 (53.1)                         234/499 (46.9)                       0.50
  IVDU                               44/92 (47.8)                           48/92 (52.2)                          
  Other                              187/342 (54.7)                         155/342 (45.3)                        
  Comorbidities                                                                                                   
    GFR (median, range)              93 (5.6--185.7)                        86 (11.7--176.7)                     \<0.0001
    BMI (median, range)              25.8 (14.8--47.7)                      25.3 (15.6--52.5)                    0.15
    Current smoker                   222/411 (54.0)                         186/411 (46.0)                       0.64
    Hypertension                     257/470 (54.7)                         213/470 (45.3)                       0.36
    Cardiovascular disease           48/88 (54.6)                           40/88 (45.4)                         0.82
    Diabetes                         69/134 (51.5)                          65/134 (48.5)                        0.71
    Hepatitis C                      78/167 (46.7)                          89/167 (53.3)                        0.07
    Hepatitis B                      50/78 (64.1)                           28/78 (35.9)                         0.04
  HIV Factors                                                                                                     
    Years since HIV diagnosis        10.9 (-0.7--29.0)                      12.5 (0.0--26.2)                     0.002
    Nadir CD4                        173.5 (0--978)                         159.5 (0--1034)                      0.1
    History of OI                    138/261 (52.9)                         123/261 (47.1)                       0.94
    CD4 count                        466.5 (2--1460)                        466 (5--2103)                        0.4
    Viral load log ≥1.68             232/404 (57.4)                         172/404 (42.3)                       0.02
    CD4 delta since diagnosis        235 (0.0--1210)                        278 (0.0--2075)                      0.02
  Current ARV regimen                                                                                             
    None                             107/167 (64.1)                         60/167 (35.9)                        0.0007
    TDF [with ]{.ul}EFV              162/295 (54.9)                         133/295 (45.1)                        
    TDF [without ]{.ul}EFV           124/279 (44.4)                         155/279 (55.6)                        
    Any regimen [without ]{.ul}TDF   103/192 (53.7)                         89/192 (46.4)                         
  Lab values                                                                                                      
    Median PTH                       58 (13.4--592.5)                       45.7 (4.5--1180)                     \<0.0001
    Median calcium level             9.2 (5.4--10.6)                        9.3 (8.0--12.3)                      \<0.0001
    Median phosphorus level          3.2 (1.2--7.5)                         3.3 (1.3--5.3)                       0.18
  Season                                                                                                          
    Summer/Fall                      271/545 (49.7)                         274/545 (50.3)                       0.01
    Winter/Spring                    225/388 (58.0)                         163/388 (42.0)                        

10.1371/journal.pone.0124168.t005

###### Risk factors associated with Vitamin D deficiency, HIV-positive patients; multivariate analysis.

![](pone.0124168.t005){#pone.0124168.t005g}

  **Risk Factor**                                      **OR (95% CI)**
  ---------------------------------------------------- -------------------
  Black race                                           3.30 (2.30--4.74)
  Higher GFR[\*](#t005fn001){ref-type="table-fn"}      1.01 (1.00--1.01)
  Winter/spring season                                 1.37 (1.03--1.83)
  Advancing age[\*](#t005fn001){ref-type="table-fn"}   0.97 (0.95--0.99)
  Treatment [\*\*](#t005fn002){ref-type="table-fn"}    
    No ARV                                             1
    Tenofovir use with efavirenz                       0.86 (0.55--1.33)
    Tenofovir use without efavirenz                    0.58 (0.37--0.89)
    Any other ARV regimen without TDF                  0.91 (0.57--1.47)

\*Odds of Vitamin D deficiency is 0.73 for every 10-year increase in age and 1.21 for every 25-point increase in GFR

\*\*at the time of Vitamin D level

Discussion {#sec010}
==========

We found a high prevalence of vitamin D deficiency among veterans in care in Atlanta. Risk factors for 25(OH)D deficiency included black race, higher BMI and winter season. These associations have been reported previously and derive from decreased synthesis of vitamin D in skin due to darker skin pigmentation and lack of sunlight exposure and/or exercise during the winter months and among obese people. \[[@pone.0124168.ref002],[@pone.0124168.ref004],[@pone.0124168.ref017]\]

Aside from these known associations, age seemed to confer a protective effect, which was more pronounced among HIV-positive patients. For each additional decade of life, people who were HIV-negative had an 8% reduction in the odds of vitamin D deficiency compared to a 29% reduction for HIV-positive patients. The changes in vitamin D status with increasing age are controversial. Original data from NHANES III documented that advancing age was associated with lower levels of 25(OH)D3, \[[@pone.0124168.ref018]\] but more recent data from NHANES 2001--2004 showed no difference in 25(OH)D by age from 12 to over 60. \[[@pone.0124168.ref014]\] Data from the Women's Interagency HIV Study (WIHS) found an association between increasing age and higher vitamin D levels in women. \[[@pone.0124168.ref019]\] Although African American patients were overall younger among both HIV-positive and negative patients, the multivariate model controlled for race, so that racial differences do not entirely explain this unexpected finding.

In a predominantly male, African-American, outpatient cohort of veterans we found a higher prevalence of Vitamin D deficiency among HIV-positive compared to HIV-negative patients (53.2 vs. 38.5%). Ormesher et al and Dao et al found a higher prevalence of deficiency among HIV-negative patients, but they used an age-matched control group from NHANES data. \[[@pone.0124168.ref012],[@pone.0124168.ref020]\] This type of matching may not account for other differences in race, geographic location or other socioeconomic factors. Few studies have compared HIV-positive to HIV-negative patients with similar demographic factors. A recent report from the WIHS demonstrated more vitamin D deficiency in HIV-positive women compared to HIV-negative women.\[[@pone.0124168.ref018]\] As supported by other studies,\[[@pone.0124168.ref009]\] these differences in vitamin D deficiency are probably not related to the patients\' underlying immune status as the majority of our patients had good CD4 counts, undetectable viral loads and were receiving HAART. Furthermore, immune status (CD4 count) and virologic status (HIVviral load) were not found to be markers for vitamin D deficiency in HIV-positive patients. It is plausible that this difference could be driven by overrepresentation of young, comparatively slimmer African American males in our HIV cohort. However, HIV infection remained as an independent association after controlling for age, BMI, race, season and gender in a multivariate model.

For HIV-positive patients, we confirmed the association of vitamin D deficiency and black race,\[[@pone.0124168.ref011],[@pone.0124168.ref012],[@pone.0124168.ref021]--[@pone.0124168.ref024]\] higher GFR, \[[@pone.0124168.ref012]\] and season. \[[@pone.0124168.ref012],[@pone.0124168.ref017],[@pone.0124168.ref021]--[@pone.0124168.ref023]\] Consistent with some published data, we identified less vitamin D deficiency in patients on tenofovir (TDF) and patients with mild renal insufficiency.\[[@pone.0124168.ref012]\] The proportion of patients on ART receiving TDF was not significantly different between patients with and without vitamin D deficiency (36.8% vs. 37.6% respectively). However, 21.1% of the patients on TDF that had vitamin D deficiency were receiving efavirenz (EFV) concomitantly in contrast to only 17.4% of those not receiving EFV with TDF. EFV has been shown to be associated with vitamin D deficiency. \[[@pone.0124168.ref008],[@pone.0124168.ref012]\] Since a protective effect for tenofovir was only observed for patients also not on Efavirenz, it is plausible that what we are observing could be explained by the deleterious effect of Efavirenz on lowering Vitamin D levels more than that of a protective effect of TDF. Alternatively, TDF has been associated with secondary hyperparathyroidism and osteomalacia. \[[@pone.0124168.ref025],[@pone.0124168.ref026]\] The elevation in PTH caused by phosphate renal loss (which is seen with TDF) \[[@pone.0124168.ref027]\] could also be mediating the observed relative increase in Vitamin D levels. In this study we did not examine the dynamic interplay between Vitamin D levels, PTH, renal function and TDF. These interactions---which might explain our observations as well as others'- are complex, poorly understood, and will require further research.

Our study confirms several of the known associations with Vitamin D deficiency. The strengths of this study include a large patient population and the ability to identify and compare risk factors among HIV positive and negative patients in a similar population based on electronic data. Some limitations need to be noted. First, we lacked patient specific data on the HIV negative patients including vitamin D dietary and supplementation history. The use of the first measured vitamin D level should minimize any bias. Second, our study may not be generalizable to other patient populations since it represents a single site study in the southern U.S. and involved mostly males. Finally, due to the cross-sectional nature of the data, we want to point out that our findings demonstrate only associations. However, prospective studies have proven associations similar to the ones reported in this paper, as well as associations with outcomes such as an increased risk of virologic failure, HIV progression and even death. \[[@pone.0124168.ref017],[@pone.0124168.ref028]\]

In summary, we identified vitamin D deficiency as a prevalent problem affecting HIV-infected patients more than other veterans in care. This deficiency is ameliorated by aging in both HIV-positive and negative veterans. In addition to age, tenofovir and kidney disease seem to confer a protective effect from vitamin D deficiency in HIV-positive patients. The clinical impact of these observations will need to be prospectively studied.
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